China Reforms Welcome, But More Needed – Frazier
This article was originally published in The Pink Sheet Daily
Executive Summary
Visiting Beijing, PhRMA chairman Kenneth Frazier noted the need for drug companies to adopt flexible pricing practices in the Chinese market, and urges China to adopt regular reimbursement review after regulatory approval and more timely updates to government drug lists.